The Swiss stock market experienced a wave of analyst rating revisions following recent quarterly reports and business updates from major corporations. Among the prominent developments, Nestlé reported its nine-month sales figures, showing organic growth accelerating to 4 percent in the months of July through September, which surpassed the analyst consensus of 3.4 percent. Volume growth improved to 2.8 percent compared to 1.5 percent in the first half of the year. Despite the figures, Nestlé shares did not build upon early gains and retreated, attributed to the strong prior stock performance and the fact that the volume pickup was partly driven by the water business during a hot summer, a division slated for a joint venture with Platinum Equity.
Bank of America analyst Nicolas Ceron in London downgraded Nestlé shares from Buy to Neutral, lowering the price target to 88 francs from 94 francs. Ceron cited future difficulties in implementing price increases and pointed to a high comparative base from the prior year in the American pet food business, alongside a 25 percent valuation premium compared to Danone, which he noted possesses a better growth profile. Conversely, Deutsche Bank upgraded Roche's non-voting equity securities (partizipationsscheine) from Hold to Buy, with pharma analyst Emmanuel Papadakis raising the price target to 500 francs from 340 francs. Papadakis acknowledged the timing was late but highlighted the commercial potential of the breast cancer drug giredestrant and modest expectations for the MS treatment fenebrutinib as potential price drivers.
UBS issued two rating adjustments. Analyst Sebastian Vogel upgraded automation specialist Belimo from Neutral to Buy, raising the twelve-month price target to 900 francs from 827 francs, driven by expectations of strong growth in the data center supplier business and profit estimates sitting ten percent above consensus. Meanwhile, UBS analyst Will Hardcastle removed the sell recommendation on Zurich Insurance shares, initiating coverage with a Neutral rating and a twelve-month price target of 620 francs, up from 520 francs, noting the rating adjustment is relative as preference is given to other European insurance equities. Additional moves included Basler Kantonalbank analyst Hans Peter Schmidlin adjusting a rating from market weight to underweight with a price target of 725 francs, previously 675 francs.
ABB shares faced downward pressure despite third-quarter results and order backlogs, leading the weekly losers among Swiss Market Index large caps. The stock slipped to third place in the year-to-date SMI rankings with a 21 percent gain since January, trailing Sandoz at 36 percent and Givaudan at 26 percent, while sitting ahead of Roche at 19 percent and Lonza at 16 percent. ABB's third-quarter operational profit (EBITA) reached 2.03 billion dollars, slightly above the 2 billion dollar analyst consensus, though falling short of the wider margins by which the company beat expectations in previous quarters, while guidance upgrades had already been anticipated by the market. External factors also weighed on sentiment, including commentary from Barclays analyst George Featherstone regarding data center beneficiaries and potential shifts stemming from an agreement between Anthropic and Nscale.
